Ben Bonifant and Keith Kelly
Payors' increased power to restrict access and contract for reduced prices – combined with the growing use of evidence-based medicine...
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.